XVIVO intends to undertake a private placement of shares

June 25, 2014, Göteborg, 5:31 p.m. – Xvivo Perfusion AB (publ) (“Xvivo” or the
“Company”) (NASDAQ OMX First North: XVIVO), announces its intention to undertake
a private placement of shares.
Xvivo intends to offer shares in a private placement, in order to raise gross
proceeds of up to SEK 50 million (the “Private Placement”). The Private
Placement is directed to Swedish and international qualified investors. The
Company retains the right in its sole discretion to increase the size of the
private placement within the current board authorization given by the general
meeting held on 29 April 2014 to an aggregate of 1,950,000 shares. In case the
right to increase the size of the Private Placement is fully exercised, the
gross proceeds will correspond to SEK 70 - 75 million.

The subscription price for the shares in the Private Placement will be
determined in a book-building process that will begin no earlier than 17:31
(CET) on June 25, 2014, and end before the commencement of trading on NASDAQ OMX
First North on June 26, 2014. The order period for the Private Placement may
close earlier at the discretion of the Company.

Payment for the shares shall be made in cash. The reason for deviating from the
shareholders’ preferential rights by conducting a directed new share issue is
that the board of directors believes that it is beneficial for the Company and
its shareholders to seize this opportunity to raise additional capital on
attractive terms, thus facilitating a faster built up of the Company’s working
capital for the U.S. and European launch of the XPS and STEEN Solution, as well
as a higher pace of investment into new indications.

The Private Placement is subject to the board of directors of Xvivo resolving on
the new issue of shares. The Board of Directors can choose to cancel the book
-building in its sole discretion for any reasons and can refrain from continuing
with the Private Placement.

Pareto Securities AB (”Pareto Securities”) has been appointed as sole bookrunner
and lead manager in connection with the Private Placement.

About Xvivo

Xvivo Perfusion is a medical technology company focused on developing optimized
solutions for organ, tissue and cell preservation in connection with
transplantation. Xvivo's shares are listed on NASDAQ OMX First North. The market
cap is approximately SEK 760 million.

IMPORTANT INFORMATION

The information in this press release is not for release, publication or
distribution, directly or indirectly, in or into the United States, Australia,
New Zeeland, Hong Kong, Japan, Canada, Singapore, Switzerland or South Africa.
The distribution of this press release in certain other jurisdictions may be
restricted. The information in this press release shall not constitute an offer
to sell or the solicitation of an offer to purchase any securities in Xvivo in
any jurisdiction. This press release does not constitute, or form part of, an
offer or solicitation to purchase or subscribe for securities in the United
States. The securities referred to herein may not be offered or sold in the
United States absent registration or an exemption from registration as provided
in the U.S. Securities Act of 1933, as amended. Xvivo does not intend to
register any portion of the offering of the securities in the United States or
to conduct a public offering of the securities in the United States. Copies of
this announcement are not being distributed or sent and may not be distributed
or sent to the United States, Australia, New Zeeland, Hong Kong, Japan, Canada,
Singapore, Switzerland or South Africa.

Xvivo has not resolved to offer to the public shares or rights in any Member
State of the European Economic Area and no prospectus or other offer
documentation has been prepared or will be prepared in connection with the
Private Placement. Within such Member States of the European Economic Area which
has implemented the Prospectus Directive (each, a “Relevant Member State”), no
action has been undertaken as of this date to make an offer to the public of
shares or rights requiring a publication of a prospectus in any Relevant Member
State. As a result hereof, the shares or rights may only be offered in Relevant
Member States: (a) to a qualified investor (as defined in the Prospectus
Directive or under applicable law. For the purposes hereof, the expression an
“offer to the public of shares or rights” in any Relevant Member State means the
communication, in any form, of sufficient information on the terms of the offer
and the shares or rights to be offered so as to enable an investor to decide to
purchase any securities, as the same may be varied in a Relevant Member State
due to the implementation of the Prospectus Directive in that Member State and
the expression “Prospectus Directive” means Directive 2003/71/EC including any
relevant implementing measure in each Relevant Member State.

Pareto Securities AB is acting for Xvivo and no one else in connection with the
Private Placement and will not be responsible to anyone other than Xvivo for
providing the protections afforded to its clients or for providing advice in
relation to the Private Placement and/or any other matter referred to in this
announcement.

Pareto Securities AB accepts no responsibility whatsoever and makes no
representation or warranty, express or implied, for the contents of this
announcement, including its accuracy, completeness or verification or for any
other statement made or purported to be made by Pareto Securities AB, or on its
behalf, in connection with Xvivo and the New Shares or the Private Placement,
and nothing in this announcement is, or shall be relied upon as, a promise or
representation in this respect, whether as to the past or future. Pareto
Securities AB accordingly disclaims to the fullest extent permitted by law all
responsibility and liability whether relating to damages, contract or otherwise
which it might otherwise have in respect of this announcement or any such
statement.

Any investors in the Private Placement will further be deemed to acknowledge (i)
the information in this press release, (ii) that the investors are not relying
(for purposes of making any investment decision or otherwise) upon any advice,
counsel or representations (whether written or oral) of Xvivo, Pareto Securities
or any of their respective affiliates, and (iii) that they have consulted with
their own legal, regulatory, tax, business, investment, financial, and
accounting advisers to the extent they have deemed necessary, and they have made
their own investment decisions based upon their own judgment and upon any advice
from such advisers as they have deemed necessary. The company has not given, and
the investors have not received from the company, any non-public information in
connection with the Private Placement.

Forward-looking statements

This press release contains forward-looking statements that reflect management’s
current views with respect to future events and potential financial performance.
Although Xvivo believes that the expectations reflected in such statements are
reasonable, no assurance can be given that such expectations will prove to have
been correct. Accordingly, results can differ materially from those set out in
the forward-looking statements as a result of various factors.
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

XVIVO Perfusion is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on June
25, 2014 at 5:31 p.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com